Collecting tumor samples to study triple-negative breast cancer treatments
Part of Cancer, Skin clinical trials.
This study collects tumor tissue from people with early-stage triple-negative breast cancer before they start neoadjuvant chemotherapy. The goal is to help researchers test new therapies and look for markers that may predict who benefits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have early-stage (stage I to III) triple-negative breast cancer
- You need small metal clips placed in the tumor before starting chemotherapy
- You can participate using French and understand the study information
- You are able to sign the consent form to join
- You are covered by a social security system
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with early-stage triple-negative breast cancer (TNBC) that has not been treated yet. Researchers want to see if tracking tumor DNA in your blood can help guide treatment decisions. You would receive standard chemotherapy and surgery, plus give blood samples.
This study tests whether a new approach using a genetic test can guide treatment for low-risk triple-negative breast cancer. It aims to help patients avoid unnecessary chemotherapy while keeping the cancer from coming back.
This study collects tumor tissue from breast cancer patients before they start chemotherapy to grow miniature versions of their tumors (organoids) in the lab. The goal is to understand how each tumor responds to treatment, which may help personalize future therapies.
This study takes small samples of your breast tumor tissue after (or during) treatment and grows them in lab animals to better study breast cancer. It may help researchers test future ideas for treating aggressive breast cancer types like triple-negative or Luminal B.
This study is testing a new way to understand your breast cancer by growing tiny tumor samples (called organoids) in the lab. It will help researchers learn more about your cancer type and could lead to better treatments.
This study looks for markers in your blood or tissue that might help predict how breast cancer will respond to treatment. It aims to improve future care by understanding these markers.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.